{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:53Z","timestamp":1792025213695,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","funder":[{"name":"Cerexa, Inc. (Oakland, CA, USA), a subsidiary of Allergan plc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40121-017-0150-5","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T07:17:07Z","timestamp":1489216627000},"page":"233-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012"],"prefix":"10.1007","volume":"6","author":[{"given":"Tiffany R.","family":"Keepers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Celeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Biek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Critchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,11]]},"reference":[{"key":"150_CR1","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103\u201320.","journal-title":"Clin Infect Dis"},{"key":"150_CR2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1179\/1973947813Y.0000000121","volume":"26","author":"HS Sader","year":"2014","unstructured":"Sader HS, Flamm RK, Jones RN. Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009\u20132011). J Chemother. 2014;26:133\u20138.","journal-title":"J Chemother"},{"key":"150_CR3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00345-013-1031-5","volume":"31","author":"G Bonkat","year":"2013","unstructured":"Bonkat G, Muller G, Braissant O, et al. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates. World J Urol. 2013;31:1427\u201332.","journal-title":"World J Urol"},{"key":"150_CR4","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/AAC.02897-15","volume":"60","author":"GV Sanchez","year":"2016","unstructured":"Sanchez GV, Babiker A, Master RN, et al. Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60:2680\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"150_CR5","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1128\/JCM.00984-13","volume":"51","author":"V Tchesnokova","year":"2013","unstructured":"Tchesnokova V, Billig M, Chattopadhyay S, et al. Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. J Clin Microbiol. 2013;51:2991\u20139.","journal-title":"J Clin Microbiol"},{"key":"150_CR6","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S0969-2126(96)00153-0","volume":"4","author":"T Skarzynski","year":"1996","unstructured":"Skarzynski T, Mistry A, Wonacott A, et al. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure.\u00a01996;4:1465\u201374.","journal-title":"Structure."},{"key":"150_CR7","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","volume":"15","author":"AS Michalopoulos","year":"2011","unstructured":"Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:e732\u20139.","journal-title":"Int J Infect Dis."},{"key":"150_CR8","unstructured":"MONUROL\u00ae (fosfomycin tromethamine). Full prescribing information, Forest Laboratories, LLC, St. Louis, MO, 2014."},{"key":"150_CR9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/phar.1434","volume":"34","author":"JL Reffert","year":"2014","unstructured":"Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2014;34:845\u201357.","journal-title":"Pharmacotherapy."},{"key":"150_CR10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","volume":"44","author":"A Dinh","year":"2012","unstructured":"Dinh A, Salomon J, Bru JP, Bernard L. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis. 2012;44:182\u20139.","journal-title":"Scand J Infect Dis"},{"key":"150_CR11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","volume":"67","author":"DE Karageorgopoulos","year":"2012","unstructured":"Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67:255\u201368.","journal-title":"J Antimicrob Chemother"},{"key":"150_CR12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","volume":"18","author":"R Raz","year":"2012","unstructured":"Raz R. Fosfomycin: an old\u2013new antibiotic. Clin Microbiol Infect. 2012;18:4\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"150_CR13","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","volume":"56","author":"RK Flamm","year":"2012","unstructured":"Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother. 2012;56:2933\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"150_CR14","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AAC.04614-14","volume":"59","author":"HS Sader","year":"2015","unstructured":"Sader HS, Flamm RK, Streit JM, Farrell DJ, Jones RN. Ceftaroline activity against bacterial pathogens frequently isolated in US medical centers: results from five years of the AWARE surveillance program. Antimicrob Agents Chemother. 2015;59:2458\u201361.","journal-title":"Antimicrob Agents Chemother"},{"key":"150_CR15","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S24. Wayne: Clinical and Laboratory Standards Institute; 2014."},{"key":"150_CR16","unstructured":"Check-Points Health. Check-MDR CT101 user manual version 2.1. Wageningen: Check-Points Health; 2012."},{"key":"150_CR17","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/AAC.00353-11","volume":"55","author":"P Bogaerts","year":"2011","unstructured":"Bogaerts P, Hujer AM, Naas T, et al. Multicenter evaluation of a new DNA microarray for rapid detection of clinically relevant bla genes from beta-lactam-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2011;55:4457\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"150_CR18","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th edn. CLSI document M07-A9. Wayne: Clinical and Laboratory Standards Institute; 2012."},{"key":"150_CR19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijantimicag.2015.08.012","volume":"46","author":"EB Hirsch","year":"2015","unstructured":"Hirsch EB, Raux BR, Zucchi PC, et al. Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates. Int J Antimicrob Agents. 2015;46:642\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"150_CR20","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/AAC.06060-11","volume":"56","author":"GV Sanchez","year":"2012","unstructured":"Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among US outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012;56:2181\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"150_CR21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/AAC.02399-13","volume":"58","author":"JA Karlowsky","year":"2014","unstructured":"Karlowsky JA, Denisuik AJ, Lagace-Wiens PR, et al. In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study. Antimicrob Agents Chemother. 2014;58:1252\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"150_CR22","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1128\/AAC.02961-15","volume":"60","author":"EB Hirsch","year":"2016","unstructured":"Hirsch EB, Zucchi PC, Chen A, et al. Susceptibility of multidrug-resistant Gram-negative urine isolates to oral antibiotics. Antimicrob Agents Chemother. 2016;60:3138\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"150_CR23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-14-66","volume":"14","author":"B Lai","year":"2014","unstructured":"Lai B, Zheng B, Li Y, Zhu S, Tong Z. In vitro susceptibility of Escherichia coli strains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: a 9-year surveillance study (2004\u20132012). BMC Infect Dis. 2014;14:66.","journal-title":"BMC Infect Dis"},{"key":"150_CR24","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1128\/AAC.02614-15","volume":"60","author":"K Linsenmeyer","year":"2016","unstructured":"Linsenmeyer K, Strymish J, Weir S, et al. Activity of fosfomycin against extended-spectrum-beta-lactamase-producing uropathogens in patients in the community and hospitalized patients. Antimicrob Agents Chemother. 2016;60:1134\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"150_CR25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1155\/2001\/601743","volume":"12","author":"T Mazzulli","year":"2001","unstructured":"Mazzulli T, Skulnick M, Small G, et al. Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents. Can J Infect Dis. 2001;12:289\u201392.","journal-title":"Can J Infect Dis."},{"key":"150_CR26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/mdr.2013.0061","volume":"19","author":"N Sato","year":"2013","unstructured":"Sato N, Kawamura K, Nakane K, Wachino J, Arakawa Y. First detection of fosfomycin resistance gene fosA3 in CTX-M-producing Escherichia coli isolates from healthy individuals in Japan. Microb Drug Resist. 2013;19:477\u201382.","journal-title":"Microb Drug Resist."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-017-0150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T10:32:46Z","timestamp":1495794766000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-017-0150-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s40121-017-0150-5","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,11]]}}}